Skip to main
TMDX
TMDX logo

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 50%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has demonstrated notable growth in the transplant market, with DCD (Donation After Circulatory Death) hearts and livers showing significant year-over-year increases of 15% and 44%, respectively, indicating a strong demand for their organ preservation technology. Despite some month-over-month fluctuations in liver transplant volumes, the overall growth in the DCD market contributed to a 7% increase in combined heart, liver, and lung transplants for the quarter to date. Furthermore, the company is positioned for potential upside with new product launches, increased adoption rates in lung transplants, and anticipated improvements in operating margins, suggesting a robust revenue forecast including an estimated $120M in 4Q24.

Bears say

TransMedics Group's stock faces a negative outlook due to a notable decline in donor organ transplants, with DBD livers and hearts experiencing a year-over-year drop of 6% and DBD hearts declining 12% month-over-month. Despite a slight increase in revenue estimates for 2026, recent group multiples have decreased from 7.2x to 6.8x, indicating declining investor confidence. Additionally, the company is exposed to various risks, including potential competition from metra and NRP, which could hinder its market share and slow growth, coupled with concerns regarding the adoption of its Organ Care System and possible regulatory challenges.

TMDX has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 50% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 10 analysts, TMDX has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.